caa a22 4500 605490961 CHVBK 20210128100507.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0727-x doi (NATIONALLICENCE)springer-10.1007/s10147-014-0727-x Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice [Elektronische Daten] [Joaquín Gavilá, Ángel Guerrero, Miguel Climent, Aranzazu Fernández, Francisco Gozalbo, María Carrascosa, Josefina Camps, Vicente Guillem, Amparo Ruiz] Background: Based on previous results obtained with non-pegylated liposomal-encapsulated doxorubicin (TLC-D99) together with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer (BC), a similar regimen was evaluated in the neoadjuvant setting in a prospectively selected series of consecutive patients with clinical stage II-III BC. Primary and secondary objectives included the rate of pathologic complete response (pCR), safety, and predictive factors of pCR. Methods: Patients received six cycles of TLC-D99 (50mg/m2 every 3weeks), paclitaxel (80mg/m2 weekly) and trastuzumab (4mg/kg initial dose and 2mg/kg weekly). All patients underwent surgery after treatment. pCR was defined as the absence of invasive cancer cells in the breast and the axilla. Results: Sixty-two patients with a median age of 46.6 years were analyzed. Stage IIIA was diagnosed in 43.5% of patients and 14.5% had inflammatory BC. Conservative surgery was performed in 46.8% of the patients and pCR was achieved in 63% (95% CI 50.5-75.5). Patients with estrogen receptor (ER)-negative tumors presented a significantly higher pCR rate than patients with ER-positive tumors (74.4 vs 43.5%; P=0.028). Forty-five patients (72.6%) completed study treatment and 80.6% received at least five treatment cycles. No patients developed congestive heart failure and 14.5% of patients showed a≥10% decrease in the left ventricular ejection fraction. Conclusion: The triple combination therapy assessed is effective and safe, offering a high pCR rate in patients with HER2-positive BC. Japan Society of Clinical Oncology, 2014 Antibodies nationallicence Breast neoplasm nationallicence Drug therapy nationallicence Prospective study nationallicence Treatment outcome nationallicence Gavilá Joaquín Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut Guerrero Ángel Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut Climent Miguel Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut Fernández Aranzazu Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut Gozalbo Francisco Pathological Anatomy Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut Carrascosa María Radiation Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut Camps Josefina Surgery Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut Guillem Vicente Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut Ruiz Amparo Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 480-489 1341-9625 20:3<480 2015 20 10147 https://doi.org/10.1007/s10147-014-0727-x text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0727-x text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Gavilá Joaquín Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Guerrero Ángel Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Climent Miguel Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Fernández Aranzazu Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Gozalbo Francisco Pathological Anatomy Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Carrascosa María Radiation Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Camps Josefina Surgery Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Guillem Vicente Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut NATIONALLICENCE 700 1- Ruiz Amparo Medical Oncology Service, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea, 31, 46009, Valencia, Spain aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 480-489 1341-9625 20:3<480 2015 20 10147